The medical community has been dealing with addiction to opioid-based pain medication for over 150 years. It is not a new issue. It has only been in recent years that the rate of addiction has reached crisis proportions. In 2016 alone, opioid overdose claimed 42,000 lives – more than the number of those lost to breast cancer.
Last year, massive cyber-security failures at Equifax exposed personal information on over 145 million consumers to criminal hackers. This information includes Social Security numbers, credit card information, driver's licenses, telephone numbers and more. It is a clear case of gross negligence on part of Equifax, which waited several months before informing consumers.
Department of Justice Announces It Will Side With Plaintiffs in Opioid Lawsuit – But Will It, Really?
Earlier this week, the current U.S. Attorney General Jefferson Sessions announced that the Department of Justice intends to file a “statement of interest” in filing its own lawsuit against opioid manufacturers. In a media statement, Sessions alleged that opioid manufacturers and distributors had used “false, deceptive, and unfair marketing” in order to market their products.
Despite demonstrated dangers and side effects, which are the primary cause of action in the dozens of lawsuits currently part of a mass tort action, the atypical antipsychotic medication Abilify remains on pharmacy shelves.
VARUBI® (rolapitant) was originally developed by Schering-Plough, which was taken over by Merck & Co. in November 2009. Currently, it has been licensed by Tesaro Inc., a relatively new biopharmaceutical company specializing in the development and marketing of cancer medications. It is primarily indicated for chemotherapy patients experiencing nausea and vomiting as a result of their treatment.
Of the five largest mass lawsuits either underway or scheduled for trial in 2018, three are about prescription drugs, with a fourth one listing a defective medical device as the cause of action. These cases involve not only negligence, failure to warn; and product defects; but in at least one of the cases the defendant is alleged to have engaged in criminal acts.
Drugmaker Allergan, which has most recently come under fire over the opioid-based medication Viberzi, has been targeted in numerous lawsuits over the years for many reasons. In the wake of 120 FDA reports of serious pancreatic injury and death attributed to Viberzi, Allergan is currently under investigation by law firms across the country on behalf of patients without gall bladders who have been injured by the medication.
Figures from the Centers for Disease Control and Prevention indicate that approximately 50,000 women a year in the U.S. suffer life-threatening complications giving birth – and as many as 900 of those women die. Those who survive often wind up disabled, traumatized and/or sterile.
The Invokana CANVAS study, mandated by the FDA as part of post-marketing requirements and sponsored by manufacturer Janssen Pharmaceuticals, has had mixed results. On one hand, patients who were treated with Invokana (canagliflozin) experienced significantly lower rates of stroke and heart attacks. On the other hand, the risk of lower limb amputations was double those of patients who took a placebo.
Ignoring its own guidelines for the assessment of cancer risks, the EPA has rejected evidence indicating that glyphosate, the active ingredient in Monsanto's controversial herbicide Roundup®, is carcinogenic.
This week, the FDA announced its approval for a new gene therapy designed to treat a rare genetic disorder that causes blindness. According to the press release, the new product is the first gene therapy to target a disorder resulting from a specific genetic mutation. This treatment offers fresh hope to those who face an inherited form of blindness.
For all his failures and incompetence, Trump has been having resounding success in one area: stacking the federal courts with right-wing hacks. So far, he has nominated 68 judges who are little more than toadies to Corporate America and the oligarchy. Nearly one-third of these nominees have been confirmed – which is no small accomplishment. It is also alarming, because these are lifetime appointments.
Attune Knee Replacement Problems are Affecting Younger People – and the Economic Consequences can be Devastating
Knee replacement is among the most common surgeries carried out today. When done correctly, total knee arthroplasty (TKA) results in positive outcomes for 90 percent of patients who undergo the procedure, enabling those who have suffered from severe knee pain to return to their daily activities.
In 2011, Covidien, a subsidiary of Medtronic, touted its ParietexTM Composite Ventral Patch as a “clinically proven collagen film technology to minimize visceral attachment...designed for optimal abdominal wall conformability in umbilical and small ventral hernia repair.” Six years later, a patient who had receive